awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34250003-7C515B53-4850-480C-B8E5-883F02E43D42
Q34250003-7C515B53-4850-480C-B8E5-883F02E43D42
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34250003-7C515B53-4850-480C-B8E5-883F02E43D42
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
P2860
Q34250003-7C515B53-4850-480C-B8E5-883F02E43D42
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34250003-7C515B53-4850-480C-B8E5-883F02E43D42
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2441efdfc98d62c53bb87b571ef4df08319a30ba
P2860
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.